Novartis AG
Triazolopyridine compounds and uses thereof
Last updated:
Abstract:
A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: ##STR00001## wherein A, R.sup.6, R.sup.7 and R.sup.8 are as defined herein.
Status:
Grant
Type:
Utility
Filling date:
6 Jun 2017
Issue date:
23 Jun 2020